BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 29174566)

  • 1. The roles of pathology in targeted therapy of women with gynecologic cancers.
    Murali R; Grisham RN; Soslow RA
    Gynecol Oncol; 2018 Jan; 148(1):213-221. PubMed ID: 29174566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for gynecologic cancers: Toward the era of precision medicine.
    Basu P; Mukhopadhyay A; Konishi I
    Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():131-136. PubMed ID: 30306576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating Precision Medicine into the Contemporary Management of Gynecologic Cancers.
    Wolford JE; Ferrigni E; Margul D; Herzog TJ
    Curr Oncol Rep; 2022 Jul; 24(7):889-904. PubMed ID: 35347591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic-Based Therapy of Gynecologic Malignancies.
    Markman M
    Acta Med Acad; 2019 Apr; 48(1):84-89. PubMed ID: 31264436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.
    Reyes HD; Thiel KW; Carlson MJ; Meng X; Yang S; Stephan JM; Leslie KK
    Mol Diagn Ther; 2014 Apr; 18(2):137-51. PubMed ID: 24403167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational selection of biomarker driven therapies for gynecologic cancers: The more we know, the more we know we don't know.
    Liu J; Westin SN
    Gynecol Oncol; 2016 Apr; 141(1):65-71. PubMed ID: 27016231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers.
    Castellano T; Moore KN; Holman LL
    Clin Ther; 2018 Mar; 40(3):372-388. PubMed ID: 29530456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of the toxicities of common targeted therapeutics for gynecologic cancers.
    Gunderson CC; Matulonis U; Moore KN
    Gynecol Oncol; 2018 Mar; 148(3):591-600. PubMed ID: 29395304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy in Gynecologic Cancers: Are We There Yet?
    Pakish JB; Jazaeri AA
    Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
    Corey L; Valente A; Wade K
    Obstet Gynecol Clin North Am; 2019 Mar; 46(1):155-163. PubMed ID: 30683261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Barroilhet L; Matulonis U
    Gynecol Oncol; 2018 Mar; 148(3):585-590. PubMed ID: 29366510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
    Kakavand H; Wilmott JS; Long GV; Scolyer RA
    Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immuno-oncology for Gynecologic Malignancies.
    How J; Patel A; Jazaeri A
    Adv Exp Med Biol; 2020; 1244():149-182. PubMed ID: 32301014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomic profiling of gynecologic cancers and implications for clinical practice.
    Prendergast EN; Elvin JA
    Curr Opin Obstet Gynecol; 2017 Feb; 29(1):18-25. PubMed ID: 27984344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic insights in gynecologic cancer.
    Roddy E; Chapman J
    Curr Probl Cancer; 2017; 41(1):8-36. PubMed ID: 28088330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
    Jazaeri A; Coleman RL; Sood AK; Frumovitz MM; Soliman PT; Shafer A; Cutrera JJ; Klinger M; Sharafi SE; Johnson CAL; Villanueva VF; Hinchcliff EM; Dickens A; Cain KE; Anderson JE; Lu KH; Westin SN
    Gynecol Oncol; 2018 Nov; 151(2):374-380. PubMed ID: 30213435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
    Kristeleit RS; Miller RE; Kohn EC
    Am Soc Clin Oncol Educ Book; 2016; 35():e259-68. PubMed ID: 27249731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node biopsy in the management of vulvar carcinoma, cervical cancer, and endometrial cancer.
    Zivanovic O; Khoury-Collado F; Abu-Rustum NR; Gemignani ML
    Oncologist; 2009 Jul; 14(7):695-705. PubMed ID: 19608640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metastatic gynecologic malignancies: advances in treatment and management.
    Chan JK; Chow S; Bhowmik S; Mann A; Kapp DS; Coleman RL
    Clin Exp Metastasis; 2018 Aug; 35(5-6):521-533. PubMed ID: 29931499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.